Society ❯ Healthcare Access ❯ Drug Affordability ❯ Public Health

Patient Advocacy

Bristol Myers Sets U.K. Price for New Schizophrenia Drug Equal to U.S., Threatens to Pull Product

The company will seek U.K. approval within weeks, tying a planned 2026 launch to acceptance of a $1,850 monthly list price.